WERFEN RECEIVES 2026 IMV ServiceTrak(TM) AWARDS FOR BEST CUSTOMER SATISFACTION, SYSTEM PERFORMANCE AND SERVICE IN COAGULATION. Aug 19, 2026, 09:37 ET BEDFORD, Mass., Aug. 19, 2026 /PRNewswire/ - Werfen today announced it has received all three 2026 IMV ServiceTrak(TM) Clinical Laboratory Awards in Coagulation (Hemostasis), earning Best Customer Satisfaction, Best System Performance, and Best Service. Based on independent feedback from laboratory professionals nationwide, the awards recognize manufacturers that deliver outstanding customer satisfaction, system reliability, and service excellence. These awards build on Werfen's leadership in the Coagulation category since its introduction in 2018 and underscore the company's long-standing commitment to delivering reliable performance, responsive support, and positive customer outcomes. The IMV ServiceTrak 2026 Clinical Laboratory Awards are based on independent research conducted with clinical laboratory professionals across the United States. Results are based on interviews from nearly 2,000 clinical testing locations representing more than 4,000 instruments. For more than 25 years, the ServiceTrak(TM) program has served as an industry benchmark for customer satisfaction, system performance, and service excellence. "We are honored to receive the 2026 IMV Awards, a recognition that reflects the quality of our products and the exceptional service we provide to our customers," said Bill Crandell, Vice President of North America Commercial Operations at Werfen. "This achievement is a testament to the dedication and specialization of our entire team - from the people who design and manufacture our innovative solutions to those who support our customers every day. Together, this commitment enables us to fulfill our purpose of Powering Patient Care." "Winning the ServiceTrak Best of Customer Satisfaction, Best System Performance and Best Service awards reflects real feedback from the clinical lab professionals who use Werfen's systems every day," said Richa Singh, VP Strategic Insights, at IMV, part of Science and Medicine Group. "These awards are grounded in independent, data-driven research, which makes them one of the most credible benchmarks in the industry." Werfen Receives 2026 IMV ServiceTrak Awards for Best Customer Satisfaction, System Performance and Service in Coagulation About Werfen's Complete Hemostasis Solution Werfen's Complete Hemostasis Solution is comprised of in vitro diagnostics systems, reagents and automation solutions used to diagnose and guide treatment of thrombotic and bleeding disorders. The ACL TOP(R) Family 70 Series provide a standardized family of systems for Hemostasis testing. The comprehensive HemosIL(R) portfolio, including routine and specialty reagents, is designed for general screening and disease-state management. For even greater productivity, HemoCell(R) Specialized Lab Automation, customized for each lab, optimizes testing workflow via specialized automation. HemoHub(R) Intelligent Data Manager provides central management of Werfen Hemostasis systems. And Werfen's award-winning* Service and Support teams partner with customers to ensure optimal instrument operation, and provide training and 24/7 Technical Support. About IMV Each year, IMV, a part of Science and Medicine Group, produces a series of proprietary ServiceTrak reports derived from research conducted directly with clinical lab professionals across the United States. The ServiceTrak Program represents an independent analysis of service trends in multiple laboratory diagnostic modalities and includes manufacturer ratings for 38 attributes to determine what drives probability of repurchase and customer satisfaction. As part of the ServiceTrak Program, awards are given to the top provider in each modality across three categories: Best of Customer Satisfaction, Best of System Performance, and Best of Service. Based on interviews from nearly 2,000 clinical testing locations and over 4,000 instruments, ServiceTrak has been the industry benchmark for over 25 years. About Werfen Werfen (www.werfen.com), founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company's clinical areas of focus include Hemostasis, Acute Care, Transfusion, Autoimmunity, and Transplant. The Hemostasis portfolio includes ACL TOP Family 70 Series, ACL TOP Family 50 Series, ACL Elite(R) Pro and ACL AcuStar(R), HemoCell Specialized Lab Automation, HemoHub Intelligent Data Manager, along with the comprehensive line of HemosIL reagents. *Recipient of the 2026 IMV ServiceTrak(TM) Best Service Award in Coagulation SOURCE Werfen

Werfen and Oxford Nanopore collaborate to enhance transplant testing. Werfen and Oxford Nanopore Technologies have expanded their collaboration to validate Werfen's transplant assays on Oxford Nanopore's sequencing platforms, aiming to deliver faster, more accurate donor-recipient matching. May 29, 2026 Werfen announced a strategic collaboration with Oxford Nanopore Technologies to validate Werfen's specialized transplant assay portfolios for use on Oxford Nanopore's sequencing platforms. Building on a collaboration between Werfen and Oxford Nanopore that began in 2020, this marks a significant milestone, combining Werfen's validated, high-precision transplant assays with Oxford Nanopore's rapid, information-rich sequencing technology. Together, the companies aim to streamline laboratory workflows, providing a fast and accurate "DNA-to-result" experience that leverages the speed and scalability of nanopore sequencing. By ensuring the optimization and compatibility of Werfen's transplant portfolio, including solutions for Human Leukocyte Antigen (HLA) typing and pre-transplant matching, with Oxford Nanopore's platforms, the aim is to enable laboratories to implement high-quality testing with reduced complexity and faster results. This is particularly critical in transplantation, where rapid, high-resolution data is essential for donor-recipient matching and long-term success.

AcouSort receives prepayment of royalties. AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum royalties for 2027 and 2028. Together with Werfen's regular 2026 minimum royalty, the total sum payable to AcouSort in early 2026 amounts to approximately USD 1.3 million. "Based on our current cash position and this prepayment together with Werfen's regular 2026 minimum royalties alone will fund AcouSort into 2027," said AcouSort's CEO Dr. Torsten Freltoft. The original agreement was signed in spring 2018. Using AcouSort acoustofluidic background technology, the parties jointly developed the solution now implemented in Werfen's groundbreaking GEM Premier 7000 system for point-of-care blood gas analysis. The hemolysis detection in GEM Premier 7000 is based upon patented acoustofluidic technology for plasma separation, combined with photometric determination. In just 45 seconds, the GEM Premier 7000 detects hemolysis, while delivering a complete menu of blood-gas results (pH, pO2, pO2, sodium, potassium, ionized calcium, chloride, glucose, lactate, hematocrit, total hemoglobin, total bilirubin and CO-Oximetry). No other terms of the License and Distribution Agreement with Werfen have been changed. In terms of liquidity, the change takes effect within Q1, while revenue recognition occurs according to applicable accounting principles. This information is information that AcouSort is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-10 17:30 CET. FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT: Torsten Freltoft, CEO Telephone: +45 2045 0854 E-mail:[email protected] ABOUT ACOUSORT AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB. Attachments AcouSort receives prepayment of royalties